Literature DB >> 33540540

Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective about the Mode of Action.

Minoru Gotoh1,2, Osamu Kaminuma2,3.   

Abstract

Owing to the successful application of sublingual immunotherapy (SLIT), allergen immunotherapy (AIT) has become one of the leading treatments for allergic diseases. Similar to the case with other AITs, such as subcutaneous and oral immunotherapies, not only the alleviation of allergic symptoms, but also the curing of the diseases can be expected in patients undergoing SLIT. However, how and why such strong efficacy is obtained by SLIT, in which allergens are simply administered under the tongue, is not clearly known. Various potential mechanisms, including the induction of blocking antibodies, T cell tolerance, regulatory B and T cells, CD103-CD11b+ classical dendritic cells, and CD206+ macrophages, and the reduction of innate lymphoid cells, mast cells, and basophils, have been suggested. Recently, through a comparative analysis between high- and non-responder patients of SLIT, we have successfully proposed several novel mechanisms. Here, we introduce our recent findings and summarize the current understanding of the mechanisms underlying the strong efficacy of SLIT.

Entities:  

Keywords:  CD4+ T cell; Japanese cedar pollinosis; apoptosis; bitter taste receptor; microarray; proteomics; thrombospondin 1

Year:  2021        PMID: 33540540      PMCID: PMC7912807          DOI: 10.3390/pathogens10020147

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  85 in total

1.  Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet.

Authors:  Minoru Gotoh; Syuji Yonekura; Toru Imai; Shinya Kaneko; Eiji Horikawa; Akiyoshi Konno; Yoshitaka Okamoto; Kimihiro Okubo
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-08

2.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

Authors:  James N Francis; Louisa K James; Giannis Paraskevopoulos; Cheukyee Wong; Moises A Calderon; Stephen R Durham; Stephen J Till
Journal:  J Allergy Clin Immunol       Date:  2008-04-18       Impact factor: 10.793

3.  Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy.

Authors:  Mongkol Lao-Araya; Esther Steveling; Guy W Scadding; Stephen R Durham; Mohamed H Shamji
Journal:  J Allergy Clin Immunol       Date:  2014-09-08       Impact factor: 10.793

4.  Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion.

Authors:  Rimpei Morita; Nathalie Schmitt; Salah-Eddine Bentebibel; Rajaram Ranganathan; Laure Bourdery; Gerard Zurawski; Emile Foucat; Melissa Dullaers; SangKon Oh; Natalie Sabzghabaei; Elizabeth M Lavecchio; Marilynn Punaro; Virginia Pascual; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2011-01-06       Impact factor: 31.745

5.  House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-gamma and IL-4 expression by circulating T lymphocytes.

Authors:  R M O'Brien; K A Byron; G A Varigos; W R Thomas
Journal:  Clin Exp Allergy       Date:  1997-01       Impact factor: 5.018

6.  Oral immunotherapy with transgenic rice seed containing destructed Japanese cedar pollen allergens, Cry j 1 and Cry j 2, against Japanese cedar pollinosis.

Authors:  Yuhya Wakasa; Hidenori Takagi; Sakiko Hirose; Lijun Yang; Mayumi Saeki; Tomoe Nishimura; Osamu Kaminuma; Takachika Hiroi; Fumio Takaiwa
Journal:  Plant Biotechnol J       Date:  2012-10-16       Impact factor: 9.803

7.  Induction of apoptosis in human basophils by anti-Fas antibody treatment in vitro.

Authors:  Kenji Matsumoto; Akihiko Maeda; Bruce S Bochner; Hiroshi Wakiguchi; Hirohisa Saito
Journal:  Int Arch Allergy Immunol       Date:  2008-05-27       Impact factor: 2.749

8.  Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

Authors:  N Mothes; M Heinzkill; K J Drachenberg; W R Sperr; M T Krauth; Y Majlesi; H Semper; P Valent; V Niederberger; D Kraft; R Valenta
Journal:  Clin Exp Allergy       Date:  2003-09       Impact factor: 5.018

9.  Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response.

Authors:  Claudia Kitzmüller; Beatrice Jahn-Schmid; Tamar Kinaciyan; Barbara Bohle
Journal:  Allergy       Date:  2019-04-10       Impact factor: 13.146

10.  Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy.

Authors:  Jorn J Heeringa; Craig I McKenzie; Nirupama Varese; Mark Hew; Amy T C M Bakx; Pei M Aui; Jennifer M Rolland; Robyn E O'Hehir; Menno C van Zelm
Journal:  Allergy       Date:  2019-11-04       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.